Benefits of Earlier Apremilast Initiation in Patients with Psoriasis and Limited Skin Involvement: Results from a Real-World Retrospective Study

By afschroeder • August 7, 2025

Armstrong A, Strober B, Gisondi P, Orroth KK, Cordey M, Kent ST, Deignan C, Jardon S, Hernandez RK, Brookhart MA, Stein Gold L. Benefits of Earlier Apremilast Initiation in Patients with Psoriasis and Limited Skin Involvement: Results from a Real-World Retrospective Study. Dermatol Ther (Heidelb). 2025 Aug 6. doi: 10.1007/s13555-025-01466-3. Epub ahead of print. PMID: 40767996.

Tags: apremilast, Dermatology, disease burden, Phosphodiesterase 4 inhibitors, psoriasis, Publications, real-world, Topical drug administration

Complete genomes of the hydrogenotrophic methanogen species -Methanospirillum stamsii Pt1 and Methanospirillum lacunae Ki8-1

Humm E, Chettiyar R, Rubbi L, Del Vecchio G, Pellegrini M, Ha SM, Gunsalus RP. Complete genomes of the hydrogenotrophic methanogen species-Methanospirillum stamsii Pt1 and Methanospirillum lacunae Ki8-1.[...]

SPECTREM Phase 3b Clinical Trial Results Through Week 16: Guselkumab Efficacy and Safety for the Treatment of Low Body Surface Area, Moderate Psoriasis With High-Impact Site Involvement

Stein Gold L, Gottlieb AB, Armstrong AW, Alkousakis T, Bissonnette R, Langley RG, Krueger J, Papp K, Choi O, Rowland K, Chan D, Jeyarajah J,[...]

A Nationwide Survey of Dermatology Faculty and Mentors on Their Advice for the Dermatology Match Process

D'Amiano AJ, Rohr B, Glick B, Hogeling M, Keller M, Sunshine J. A Nationwide Survey of Dermatology Faculty and Mentors on Their Advice for the[...]